Abstract
The rapid increase of human infections by multidrug-resistant (MDR) Gram-negative pathogens poses a serious health threat and demands the identification of new strategies, molecular targets, and agents for the treatment of Gram-negative bacterial infections. The biosynthesis of lipid A, the membrane-anchoring portion of lipopolysaccharide (LPS), is one promising target for novel antibiotic design because lipid A is essential for LPS assembly in most Gram-negative bacteria. The first three enzymes in the biosynthesis of lipid A, UDP-N-acetylglucosamine acyltransferase (LpxA), UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase (LpxC) and UDP- 3-O-(R-3-hydroxyacyl)glucosamine N-acyltransferase (LpxD), have emerged as an attractive Gram-negative antibacterial molecular target. In this article, we review recent advances in the studies on the structures and the structure-based drug designs of the three enzymes.
Keywords: Multidrug-resistant pathogens, lipid A biosynthesis, acyltransferase, deacetylase, chemotherapy.
Current Pharmaceutical Design
Title:Lipid A Biosynthesis of Multidrug-Resistant Pathogens - A Novel Drug Target
Volume: 19 Issue: 36
Author(s): Chang-Ro Lee, Jung Hun Lee, Byeong Chul Jeong and Sang Hee Lee
Affiliation:
Keywords: Multidrug-resistant pathogens, lipid A biosynthesis, acyltransferase, deacetylase, chemotherapy.
Abstract: The rapid increase of human infections by multidrug-resistant (MDR) Gram-negative pathogens poses a serious health threat and demands the identification of new strategies, molecular targets, and agents for the treatment of Gram-negative bacterial infections. The biosynthesis of lipid A, the membrane-anchoring portion of lipopolysaccharide (LPS), is one promising target for novel antibiotic design because lipid A is essential for LPS assembly in most Gram-negative bacteria. The first three enzymes in the biosynthesis of lipid A, UDP-N-acetylglucosamine acyltransferase (LpxA), UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase (LpxC) and UDP- 3-O-(R-3-hydroxyacyl)glucosamine N-acyltransferase (LpxD), have emerged as an attractive Gram-negative antibacterial molecular target. In this article, we review recent advances in the studies on the structures and the structure-based drug designs of the three enzymes.
Export Options
About this article
Cite this article as:
Lee Chang-Ro, Lee Hun Jung, Jeong Chul Byeong and Lee Hee Sang, Lipid A Biosynthesis of Multidrug-Resistant Pathogens - A Novel Drug Target, Current Pharmaceutical Design 2013; 19 (36) . https://dx.doi.org/10.2174/13816128113199990494
DOI https://dx.doi.org/10.2174/13816128113199990494 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulation of Inflammatory Response to Implanted Biomaterials Using Natural Compounds
Current Pharmaceutical Design Current Understanding of Epigenetics Driven Therapeutic Strategies in Colorectal Cancer Management
Endocrine, Metabolic & Immune Disorders - Drug Targets Disease-Modifying Effect of Anthraquinone Prodrug with Boswellic Acid on Collagenase-Induced Osteoarthritis in Wistar Rats
Inflammation & Allergy - Drug Targets (Discontinued) Hydroxysafflor Yellow A Reprograms TLR9 Signalling Pathway in Ischaemic Cortex after Cerebral Ischaemia and Reperfusion
CNS & Neurological Disorders - Drug Targets Emergence of Traditionally Used Foods as Today’s Probioticslong Journey
Current Traditional Medicine Nitric Oxide and Pancreatic Cancer Pathogenesis, Prevention, and Treatment
Current Pharmaceutical Design Supramolecular Chiro-Biomedical Assays and Enantioselective HPLC Analyses for Evaluation of Profens as Non-Steroidal Anti-Inflammatory Drugs, Potential Anticancer Agents and Common Xenobiotics
Current Drug Discovery Technologies The APOE Genotype: Modification of Therapeutic Responses in Alzheimer's Disease
Current Pharmaceutical Design A Highlight on Lipid Based Nanocarriers for Transcutaneous Immunization
Current Pharmaceutical Biotechnology Effects of Resveratrol and other Polyphenols on Sirt1: Relevance to Brain Function During Aging
Current Neuropharmacology Targeting the Multidrug ABCG2 Transporter with Flavonoidic Inhibitors: In Vitro Optimization and In Vivo Validation
Current Medicinal Chemistry Protein N-Glycosylation in the Baculovirus-Insect Cell System
Current Drug Targets Targeting CNS Transporters for Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Identification of Moesin as a Novel Autoantigen in Patients with Sjögren’s Syndrome
Protein & Peptide Letters Hetero-Oligomerization of Chemokine Receptors: Diversity and Relevance for Function
Current Medicinal Chemistry Induced Human Bone Marrow Stromal Cells Differentiate into Neural Cells by bFGF and Cocultured with Olfactory Ensheathing Cells
Current Stem Cell Research & Therapy Insight into Cocaine-Induced Neural and Behavioral Adaptations Using Genome-Wide Expression Profiling and Epigenomic Analysis
Current Psychopharmacology Fractionation Techniques Improve the Proteomic Analysis of Human Serum
Current Pharmaceutical Analysis Different Types of Cell Death in Organismal Aging and Longevity: State of the Art and Possible Systems Biology Approach
Current Pharmaceutical Design Translating Mismatch Repair Mechanism into Cancer Care
Current Drug Targets